Cited by 421Schizophrenia research and treatmentPharmacology and Obesity TreatmentParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Open access

Koro, Carol E, Fedder, Donald O, L'Italien, Gilbert J, Weiss, SheilaS, Magder, LaurenceS, Kreyenbuhl, Julie, Revicki, DennisA, Buchanan, RobertW·2002·BMJ

DOI 10.1136/bmj.325.7358.243PMC PMC117636

Open this paper in CoChat — free account Open PDF

Abstract

Objective : To quantify the association between olanzapine and diabetes. Design : Population based nested case-control study. Setting : United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants : 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures : Diagnosis and treatment of diabetes. Results : Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion : Olanzapine is associated with a clinically important and significant increased risk of diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.325.7358.243

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Logistic Regression: A Self-Learning Text.
Selvin, S., & Kleinbaum, D. G. (1996) · Journal of the American Statistical Association · doi:10.2307/2291427 · Cited by 1,628
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 624
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsy
Isojärvi, J. I. T., Rättyä, J., Myllylä, V. V., Knip, M., Koivunen, R. M., Pakarinen, A., Tekay, A., & Tapanainen, J. S. (1998) · Annals of Neurology · doi:10.1002/ana.410430406 · Cited by 342
The General Practice Research Database
Wood, L., & Martínez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 330
Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related Psychoses
Melkersson, K. I., Hulting, A., & Brismar, K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 300
THE METABOLIC EFFECTS OF EPINEPHRINE AND RELATED AMINES
Ellis, S. (1956) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06998-4 · Cited by 288
A Retrospective Comparison of Weight, Lipid, and Glucose Changes Between Risperidone- and Olanzapine-Treated Inpatients
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267

Show all 30 references

Research works printed but not linked: 2

Caro, 2000, Atypical antipsychotics and the risk of developing diabetes. International Society for Pharmacoeconomics and Outcomes Research European meeting, Belgium, 2000., Value Health, 3, MH2
10.1176/appi.ajp.124.7.978 · DOI

Sorted by citations

Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Psychosocial care for people with diabetes: a position statement of the American Diabetes Association
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2016) · Diabetes Care · doi:10.2337/dc16-2053 · Cited by 1,072
Mood disorders in the medically ill: scientific review and recommendations
Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.001 · Cited by 1,071
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citation
Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
Musselman, D. L., Betan, E. J., Larsen, H., & Phillips, L. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00569-9 · Cited by 687
Endocrine disrupters as obesogens
Grün, F., & Blumberg, B. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.02.018 · Cited by 586
A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445
Modern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 434
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362
Our Reviewers
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 355
The relationship between time since registration and measured incidence rates in the General Practice Research Database
Lewis, J. D., Bilker, W. B., Weinstein, R. B., & Strom, B. L. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1115 · Cited by 342
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2020
(2019) · Diabetes Care · doi:10.2337/dc20-s005 · Cited by 365
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 330
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P. C., Evins, A. E., Hayden, D. L., Weber, M., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 320
Introduction: Methods, Commentary, and Summary
Alexopoulos, G. S., Streim, J. E., Carpenter, D. P., & Docherty, J. P. (2004) · The Journal of Clinical Psychiatry · Cited by 316
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071065 · Cited by 315
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s005 · Cited by 299
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 271
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M. W., Kaser, S., Rettenbacher, M. A., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 265
Adverse Metabolic Effects Associated with Atypical Antipsychotics
Melkersson, K. I., & Dahl, M. (2004) · Drugs · doi:10.2165/00003495-200464070-00003 · Cited by 245
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 232
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225
Metabolic issues and cardiovascular disease in patients with psychiatric disorders
Casey, D. E. (2005) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2005.01.046 · Cited by 214
Atypical antipsychotics and glucose dysregulation: a systematic review
Jin, H., Meyer, J. M., & Jeste, D. V. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.024 · Cited by 198
Minireview: The Case for Obesogens
Grün, F., & Blumberg, B. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0485 · Cited by 188
Issues relating to study design and risk of bias when including non‐randomized studies in systematic reviews on the effects of interventions
Higgins, J. P., Ramsay, C., Reeves, B. C., Deeks, J. J., Shea, B., Valentine, J. C., Tugwell, P., & Wells, G. (2013) · Research Synthesis Methods · doi:10.1002/jrsm.1056 · Cited by 183
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s004 · Cited by 191
Abnormal glucose metabolism in patients treated with antipsychotics
Scheen, A. J., & Hert, M. A. F. D. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.01.003 · Cited by 177
Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in Dogs
Ader, M., Kim, S. P., Catalano, K. J., Ionut, V., Hücking, K., Richey, J. M., Kabir, M., & Bergman, R. N. (2005) · Diabetes · doi:10.2337/diabetes.54.3.862 · Cited by 163
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett, A. H., Mackin, P., Chaudhry, I. B., Farooqi, A., Gadsby, R., Heald, A. H., Hill, J., Millar, H. L., Peveler, R., Rees, A., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107075509 · Cited by 168
Patients on Atypical Antipsychotic Drugs
Lean, M. E. J., & Pajonk, F. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1597 · Cited by 165
3. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Medical Care in Diabetes—2018
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc18-s003 · Cited by 175
Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 147
Schizophrenia, the metabolic syndrome and diabetes
Holt, R. I. G., Peveler, R., & Byrne, C. D. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01199.x · Cited by 139
The cardiovascular and respiratory health of people with schizophrenia
Filik, R., Sipos, A., Kehoe, P. G., Burns, T., Cooper, S. J., Stevens, H., Laugharne, R., Young, G., Perrington, S., McKendrick, J., et al. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00768.x · Cited by 134
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey
Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142281.85207.d5 · Cited by 133
Atypical Antipsychotics and Metabolic Dysregulation
Nasrallah, H. A., & Newcomer, J. W. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142282.62336.e9 · Cited by 132
Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10cs06070blu · Cited by 129
Self-citation
Differential metabolic effects of antipsychotic treatments
Haupt, D. W. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.003 · Cited by 129
Cardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 135
Antipsychotic-Induced Type 2 Diabetes: Evidence From a Large Health Plan Database
Gianfrancesco, F. D., White, R., Wang, R., & Nasrallah, H. A. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000085404.08426.3a · Cited by 122
Metabolic risk during antipsychotic treatment
Newcomer, J. W. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.003 · Cited by 126
Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J. (2008) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-6-105 · Cited by 122
A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Dixon, L. B., Kreyenbuhl, J. A., Dickerson, F., Donner, T. W., Brown, C. H., Wolheiter, K., Postrado, L. T., Goldberg, R. W., Fang, L., Marano, C. M., et al. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.892 · Cited by 115
Self-citation
Risk for coronary heart disease in people with severe mental illness
Osborn, D., Nazareth, I., & King, M. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.104.008060 · Cited by 119
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Cohen, D., Stolk, R. P., Grobbee, D. E., & Wied, C. C. G. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1261 · Cited by 115
Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring
ZITO, J. M., Derivan, A., Kratochvil, C. J., Safer, D. J., Fegert, J. M., & Greenhill, L. L. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-24 · Cited by 114
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Lambert, B. L., Cunningham, F. E., Miller, D. R., Dalack, G. W., & Hur, K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj289 · Cited by 113
Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients
Citrome, L., Jaffe, A. B., Levine, J., Allingham, B., & Robinson, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1006 · Cited by 111
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer, J. W. (2004) · PubMed · Cited by 109
The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study
Yood, M. U., DeLorenze, G. N., Quesenberry, C. P., Oliveria, S. A., Tsai, A., Willey, V. J., McQuade, R. D., Newcomer, J. W., & L'Italien, G. J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1781 · Cited by 106
Self-citation
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses
Melkersson, K. I., & Dahl, M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1529-4 · Cited by 103
3. Comprehensive Medical Evaluation and Assessment of Comorbidities
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s006 · Cited by 104
Olanzapine in the Treatment of Aggression and Tics in Children with Tourette's Syndrome—A Pilot Study
Stephens, R. J., Bassel, C., & Sandor, P. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/1044546041648959 · Cited by 102
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Buckley, P. F., Miller, D. D., SINGER, B., ARENA, J., & Stirewalt, E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.010 · Cited by 102
Schizophrenia: who is at risk? Who is a case?
Verdoux, H., & Cougnard‐Grégoire, A. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000201496.23259.85 · Cited by 102
Use and Safety of Antipsychotics in Behavioral Disorders in Elderly People With Dementia
Gareri, P., Fazio, P. D., Manfredi, V. G. L., & Sarro, G. D. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a6096e · Cited by 107
Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK
Taylor, S., Taylor, R. J., Lustig, R. L., Schuck‐Paim, C., Haguinet, F., Webb, D. J., Logie, J. W., Matias, G., & Fleming, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009337 · Cited by 98
Risk of Diabetes Mellitus Associated With Atypical Antipsychotic Use Among Patients With Bipolar Disorder
Guo, J. J., Keck, P. E., Corey‐Lisle, P. K., Li, H., Jiang, D., Jang, R., & L'Italien, G. J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0707 · Cited by 91
Self-citation
Effects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men
Vidarsdóttir, S., van Weenen, J. E. D. L., Frölich, M., Roelfsema, F., Romijn, J. A., & Pijl, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1815 · Cited by 91
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
Bernardo, M., Rico‐Villademoros, F., García‐Rizo, C., Rojo, R., & Gómez‐Huelgas, R. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01689-8 · Cited by 92
First-Episode Schizophrenia
Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 86
Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics
Lublin, H., Eberhard, J., & Levander, S. E. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00001 · Cited by 86
Incidence of First Stroke in Pregnant and Nonpregnant Women of Childbearing Age: A Population‐Based Cohort Study From England
Ban, L., Sprigg, N., Sultan, A. A., Nelson‐Piercy, C., Bath, P. M., Ludvigsson, J. F., Stephansson, O., & Tata, L. J. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004601 · Cited by 87
Racial Disparity in the Pharmacological Management of Schizophrenia
Kreyenbuhl, J. A., ZITO, J. M., Buchanan, R. W., Soeken, K. L., & Lehman, A. F. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006996 · Cited by 78
Self-citation
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia
Mortimer, A. M., Martin, S. D., Löo, H., & Peuskens, J. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00002 · Cited by 81
Belgian consensus on metabolic problems associated with atypical antipsychotics
Nayer, A. D., Hert, M. D., Scheen, A. J., Gaal, L. V., Peuskens, J., & on behalf of the Consensus Group (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500510018310 · Cited by 80
Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone
Weiden, P. J., Newcomer, J. W., Loebel, A. D., Yang, R., & Lebovitz, H. E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301482 · Cited by 78
Do Certain Atypical Antipsychotics Increase the Risk of Diabetes? A Critical Review of 17 Pharmacoepidemiologic Studies
Ramaswamy, K., Masand, P. S., & Nasrallah, H. A. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600801234 · Cited by 77
Risk of weight gain for specific antipsychotic drugs: a meta-analysis
Spertus, J. V., Horvitz-Lennon, M. V., Abing, H. K., & Normand, S. T. (2018) · Schizophrenia · doi:10.1038/s41537-018-0053-9 · Cited by 81
Antipsychotics and Diabetes: An Age-Related Association
Hammerman, A., Dreiher, J., Klang, S. H., Munitz, H., Cohen, A. D., & Goldfracht, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l015 · Cited by 75
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Llorente, M. D., & Urrutia, V. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.18 · Cited by 77
[Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry].
Ruiz, J. S., García, J. B., Ruiloba, J. V., Ubago, J. G., & González, M. P. G.-P. (2008) · Actas Españolas de Psiquiatría · Cited by 74
Association between antipsychotic drugs and diabetes
Holt, R. I. G., & Peveler, R. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00495.x · Cited by 73
Testing for diabetes in hospitalised patients prescribed antipsychotic drugs
Taylor, D. M., Young, C., Esop, R., Paton, C., & Walwyn, R. E. A. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.185.2.152 · Cited by 73
Comparative Study of the Development of Diabetes Mellitus in Patients Taking Risperidone and Olanzapine
Fuller, M. A., Shermock, K. M., Secic, M., & Grogg, A. L. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.8.1037.32876 · Cited by 73
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 74
Antidepressants and risk of first-time hospitalization for myocardial infarction: A population-based case-control study
Monster, T. B. M., Johnsen, S. P., Olsen, M. L., McLaughlin, J. K., & Sørensen, H. T. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.027 · Cited by 71
Antipsychotics and diabetes: review of non-prospective data
Haddad, P. M. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s80 · Cited by 71
Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients
Smith, R. C., Lindenmayer, J., Bark, N. M., Warner‐Cohen, J., Vaidhyanathaswamy, S., & Khandat, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005110 · Cited by 70
Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus
Andrade, S. E., Lo, J. C.-M., Roblin, D. W., Fouayzi, H., Connor, D. F., Penfold, R. B., Chandra, M., Reed, G. W., & Gurwitz, J. H. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0855 · Cited by 70
Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12 103 individuals with and without contact with psychiatric services
Tidemalm, D., Waern, M., Stefansson, C.-G., Elofsson, S., & Runeson, B. (2008) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-4-23 · Cited by 68
Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data
Bushe, C., & Leonard, B. E. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.47.s87 · Cited by 68
Update on Psychotropic Medication Use in Renal Disease
Cohen, L. M., Tessier, E. G., Germain, M. J., & Levy, N. B. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.1.34 · Cited by 65
Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
Olfson, M., Marcus, S. C., & Ascher‐Svanum, H. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm033 · Cited by 65
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
Holt, R. I. G., & Peveler, R. (2006) · Diabetologia · doi:10.1007/s00125-006-0279-3 · Cited by 65
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
Second-Generation Antipsychotic Exposure and Metabolic-Related Disorders in Patients With Schizophrenia
Reist, C., Mintz, J., Albers, L. J., Jamal, M. M., Szabó, S., & Özdemir, V. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e5126 · Cited by 64
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study
Olié, J., Spina, E., Murray, S., & Yang, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182121.59296.70 · Cited by 64
Weight gain and new onset diabetes associated with olanzapine and risperidone
Farwell, W. R., Stump, T. E., Wang, J., Tafesse, E., L'Italien, G. J., & Tierney, W. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.40126.x · Cited by 64
Self-citation
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients
Ruaño, G., Goethe, J. W., Caley, C. F., Woolley, S. B., Holford, T. R., Kocherla, M., Windemuth, A., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001944 · Cited by 65
Sleep-Related Eating Disorder Induced by Risperidone
Lu, M., & Shen, W. W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0220a · Cited by 60
Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus
Citrome, L., & Jaffe, A. B. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d142 · Cited by 60
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 58

Authors: Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R.
Affiliations: University of Maryland, Baltimore (US)
Corresponding author: Koro, Carol E
ORCID: Kreyenbuhl, Julie
Venue: BMJ
Publisher: BMJ
Published: 2002-08-03
Volume: 325
Issue: 7358
Pages: 243
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.325.7358.243
PMC: PMC117636
OpenAlex: W2160802754
Cited by: 421
References: 30
Citations by year: 2026: 3 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 9
FWCI: 37.10
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
Locations: BMJ (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords: olanzapine, risperidone, schizophrenia, diabetes risk, antipsychotic drugs, adverse drug reactions, typical antipsychotics, type 2 diabetes
MeSH terms: Olanzapine, Adult, Aged, Benzodiazepines, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pirenzepine, Regression Analysis, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Odds Ratio, Case-Control Studies, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks